Skip to main content
Clinical Trials/NCT00854230
NCT00854230
Withdrawn
Phase 4

Pharmacotherapy for HIV Infected Patients With Alcohol Problems

VA Connecticut Healthcare System0 sitesJanuary 2009

Overview

Phase
Phase 4
Intervention
Naltrexone
Conditions
HIV Infection
Sponsor
VA Connecticut Healthcare System
Primary Endpoint
Frequency of heavy drinking
Status
Withdrawn
Last Updated
14 years ago

Overview

Brief Summary

This is a randomized double blind clinical trial to test the effect of Naltrexone on HIV infected heavy drinkers. The study will select 40 HIV positive patients who meet criteria for heavy drinking. Treatments include Naltrexone (25-100mg)and placebo. Patients will be treated, followed up, and assessed for a duration of 12 weeks.

The investigators associated hypotheses Hypothesis 1: Naltrexone will reduce the frequency of heavy drinking. Hypothesis 2: Naltrexone will lead to maintenance or improvement in CD4 lymphocyte count and decreased HIV RNA levels.

Hypothesis 3: Naltrexone will lead to a reduction in sexual risk behaviors. Hypothesis 4: Naltrexone will lead to improved adherence to HAART. Hypothesis 5 (Exploratory): Naltrexone will be well-tolerated with minimal side effects and patients will exhibit good treatment retention.

Registry
clinicaltrials.gov
Start Date
January 2009
End Date
January 2010
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
VA Connecticut Healthcare System
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Be HIV-positive.
  • Report heavy drinking 4 or more times in the past 4 weeks. Heavy drinking is defined as 4 or more drinks for women and 5 or more drinks for men on any occasion.
  • Not be abstinent from alcohol for greater than 30 days.
  • Be at least 18 years old.
  • Be able to understand English and provide informed consent

Exclusion Criteria

  • Be psychotic or severely psychiatrically disabled.
  • Have medical conditions that would preclude completing or be of harm during the course of the study.
  • Have laboratory or clinical evidence of significant liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of the normal range) or cirrhosis.
  • Have a known contraindication to naltrexone therapy (e.g. taking opioid medication for pain).
  • Be pregnant, nursing or unable to use an effective method of birth control (women).
  • Subjects who are taking or use narcotics will not be included because naltrexone will precipitate withdrawal.

Arms & Interventions

1

Naltrexone

Intervention: Naltrexone

2

Intervention: Naltrexone

Outcomes

Primary Outcomes

Frequency of heavy drinking

Time Frame: 12 weeks

Secondary Outcomes

  • HIV biological markers(12 weeks)
  • Sexual risk behavior(12 weeks)
  • Tolerability and retention in alcohol treatment(12 weeks)

Similar Trials